【臺灣臨床藥學雜誌】通訊積分_頑固/復發型瀰漫性大B細胞淋巴瘤新藥-Polatuzumab vedotin(30-1第2篇)
30-1-2通訊積分截止答題
This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy
Google Forms